1923 related articles for article (PubMed ID: 30907320)
1. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
Pinheiro L; Faustino C
Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
3. [Alzheimer disease: cellular and molecular aspects].
Octave JN
Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
[TBL] [Abstract][Full Text] [Related]
4. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
5. Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.
Behl T; Kaur I; Fratila O; Brata R; Bungau S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050199
[TBL] [Abstract][Full Text] [Related]
6. Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?
Dunys J; Valverde A; Checler F
J Biol Chem; 2018 Oct; 293(40):15419-15428. PubMed ID: 30143530
[TBL] [Abstract][Full Text] [Related]
7. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
[TBL] [Abstract][Full Text] [Related]
8. [Recent progress in the development of disease-modifying therapies for Alzheimer's disease].
Abe K
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Feb; 30(1):1-8. PubMed ID: 20297736
[TBL] [Abstract][Full Text] [Related]
9. Synaptic changes in Alzheimer's disease and its models.
Pozueta J; Lefort R; Shelanski ML
Neuroscience; 2013 Oct; 251():51-65. PubMed ID: 22687952
[TBL] [Abstract][Full Text] [Related]
10. Emerging beta-amyloid therapies for the treatment of Alzheimer's disease.
Conway KA; Baxter EW; Felsenstein KM; Reitz AB
Curr Pharm Des; 2003; 9(6):427-47. PubMed ID: 12570807
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's disease pathogenesis and therapeutic interventions.
Parihar MS; Hemnani T
J Clin Neurosci; 2004 Jun; 11(5):456-67. PubMed ID: 15177383
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's disease: The role of proteins in formation, mechanisms, and new therapeutic approaches.
Gholami A
Neurosci Lett; 2023 Nov; 817():137532. PubMed ID: 37866702
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
14. Ibuprofen and lipoic acid codrug 1 control Alzheimer's disease progression by down-regulating protein kinase C ε-mediated metalloproteinase 2 and 9 levels in β-amyloid infused Alzheimer's disease rat model.
Zara S; Rapino M; Sozio P; Di Stefano A; Nasuti C; Cataldi A
Brain Res; 2011 Sep; 1412():79-87. PubMed ID: 21820649
[TBL] [Abstract][Full Text] [Related]
15. Beta-amyloid, neuronal death and Alzheimer's disease.
Carter J; Lippa CF
Curr Mol Med; 2001 Dec; 1(6):733-7. PubMed ID: 11899259
[TBL] [Abstract][Full Text] [Related]
16. Alzheimer's disease: Molecular aspects and treatment opportunities using herbal drugs.
Thakral S; Yadav A; Singh V; Kumar M; Kumar P; Narang R; Sudhakar K; Verma A; Khalilullah H; Jaremko M; Emwas AH
Ageing Res Rev; 2023 Jul; 88():101960. PubMed ID: 37224884
[TBL] [Abstract][Full Text] [Related]
17. Disease-modifying therapies in Alzheimer's disease: how far have we come?
Hüll M; Berger M; Heneka M
Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
[TBL] [Abstract][Full Text] [Related]
18. Alzheimer's disease-associated neurotoxic mechanisms and neuroprotective strategies.
Pereira C; Agostinho P; Moreira PI; Cardoso SM; Oliveira CR
Curr Drug Targets CNS Neurol Disord; 2005 Aug; 4(4):383-403. PubMed ID: 16101556
[TBL] [Abstract][Full Text] [Related]
19. Status and future directions of clinical trials in Alzheimer's disease.
Plascencia-Villa G; Perry G
Int Rev Neurobiol; 2020; 154():3-50. PubMed ID: 32739008
[TBL] [Abstract][Full Text] [Related]
20. Roles of glycogen synthase kinase 3 in Alzheimer's disease.
Cai Z; Zhao Y; Zhao B
Curr Alzheimer Res; 2012 Sep; 9(7):864-79. PubMed ID: 22272620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]